Comparison of Atovaquone and Azithromycin with Trimethoprim-Sulfamethoxazole for the Prevention of Serious Bacterial Infections in Children with HIV Infection
Open Access
- 1 January 2005
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 40 (1) , 136-145
- https://doi.org/10.1086/426074
Abstract
Background. Trimethoprim-sulfamethoxazole (TMP-SMZ) has been used extensively for the prevention of Pneumocystis carinii (also referred to as “Pneumocystis jiroveci”) pneumonia (PCP) and other opportunistic infections in human immunodeficiency virus (HIV)—infected children. Because the efficacy of TMP-SMZ for treatment of bacterial infections is limited, it is sometimes poorly tolerated, and there is risk of emergence of drug-resistant strains associated with widespread use, we evaluated a regimen that included atovaquone and azithromycin. Methods. A randomized, double-blind, placebo-controlled trial was designed to determine whether atovaquone-azithromycin had equivalent efficacy to TMP-SMZ for the prevention of serious bacterial infections and to compare the long-term tolerance, PCP breakthrough rates, and nonserious bacterial infection rates among HIV-infected children aged 3 months to 19 years. Children qualified for PCP prophylaxis (on the basis of Centers for Disease Control and Prevention recommendations) were randomized to receive atovaquone-azithromycin or TMP-SMZ daily for ⩾2 years. Results. Data from 366 of the 369 eligible patients (median duration of follow-up, 3 years) showed that the estimated rates of serious bacterial infection—related events were lower among atovaquone-azithromycin recipients than among TMP-SMZ recipients (17.3 vs. 24.2 events per 100 patient-years; difference, 6.9 events per 100 patient-years; 95% confidence interval [CI], -0.22 to 14.12). Rates for all end points (serious bacterial infection, PCP, Mycobacterium avium complex infection, and serious and nonserious bacterial infection—related deaths) were 19.7 and 27.7 events per 100 patient-years, respectively (difference, 7.9 events per 100 patient-years; 95% CI, -0.28 to 15.54 events per 100 patient-years). The results marginally favored atovaquone-azithromycin therapy statistically. Atovaquone-azithromycin and TMP-SMZ therapies had similar adverse event profiles. Conclusions. We conclude that, in HIV-infected children, atovaquone-azithromycin is as effective as TMP-SMZ for the prevention of serious bacterial infections and is similarly tolerated.Keywords
This publication has 21 references indexed in Scilit:
- Multicentre comparative study of the efficacy and safety of azithromycin compared with amoxicillin/clavulanic acid in the treatment of paediatric patients with otitis mediaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- A Controlled Trial of Trimethoprim–Sulfamethoxazole or Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis carinii Pneumonia in Patients with the Acquired Immunodeficiency SyndromeNew England Journal of Medicine, 1992
- Survival in Children with Perinatally Acquired Human Immunodeficiency Virus Type 1 InfectionNew England Journal of Medicine, 1989
- Regression Analysis of Multivariate Incomplete Failure Time Data by Modeling Marginal DistributionsJournal of the American Statistical Association, 1989
- Prophylaxis of opportunistic infections in individuals infected with HIVAIDS, 1989
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982
- An Outbreak of Community-AcquiredPneumocystis cariniiPneumoniaNew England Journal of Medicine, 1981
- Pneumocystis cariniiPneumonia and Mucosal Candidiasis in Previously Healthy Homosexual MenNew England Journal of Medicine, 1981
- Successful Chemoprophylaxis forPneumocystis cariniiPneumonitisNew England Journal of Medicine, 1977
- Hodgkin's disease of the jejunum. Perforation during radiation therapyArchives of internal medicine (1960), 1968